Notably, the expression of TIM-3 and LAG-3 immune checkpoints is relatively low in gliomas [11], and as such these therapeutic targets are unlikely to be beneficial for the treatment of patients with glioma for most patients and especially as a monotherapy. Here, LAG3 is linked to central nervous system cancer.